Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAGUE-17: LAA Closure vs NOACs in AF
NCT02426944Phase 4Completed
- Sponsor
- Charles University
- Start
- Oct 2015
- Primary completion
- Jul 2019
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Atrial fibrillation (AFib) (2 arms), sponsored by Charles University. Primary endpoint: Composite of stroke, TIA, systemic cardioembolic event, clinically significant bleeding, cardiovascular death, or significant peri-procedural/device-related complication at 24 months. Started Oct 2015; status: completed.
02
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02426944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02426944.